Scarica l'app Stockscreener
2.345
1.87%
-0.055
Century Therapeutics Inc Borsa (IPSC) Ultime notizie
IPSC Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Stock ReactionEstimate Dispersion - dars.gov.et
IPSCCentury Therapeutics Inc Short Interest - Finviz
Price to sales forward of Century Therapeutics, Inc. – NASDAQ:IPSC - TradingView
IPSC News | CENTURY THERAPEUTICS INC (NASDAQ:IPSC) - ChartMill
Century Therapeutics, Inc.(NasdaqCM: IPSC) added to Russell 2000 Index - marketscreener.com
Century Therapeutics, Inc.(NasdaqCM: IPSC) added to Russell 2000 Value Benchmark - marketscreener.com
Century Therapeutics, Inc.(NasdaqCM:IPSC) added to Russell Microcap Value Benchmark Index - marketscreener.com
Century Therapeutics, Inc.(NasdaqCM: IPSC) added to Russell Microcap Index - marketscreener.com
Century Therapeutics, Inc. Actuals & Estimates (NASDAQ:IPSC) - TradingView
Enterprise value to EBIT forward of Century Therapeutics, Inc. – NASDAQ:IPSC - TradingView
Price to earnings forward of Century Therapeutics, Inc. – NASDAQ:IPSC - TradingView
IPSC Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Century Therapeutics, Inc. – NASDAQ:IPSC - TradingView
Century Therapeutics updates its CAR-T pipeline, shares trade on Nasdaq - AD HOC NEWS
Century Therapeutics Inc (IPSC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight - GlobeNewswire Inc.
Century Therapeutics Inc (IPSC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Century Therapeutics Inc (IPSC) Institutional Confidence - TradingKey
Century Therapeutics Inc (IPSC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Century Therapeutics Inc (IPSC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Century Therapeutics Inc (IPSC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Century Therapeutics Inc (IPSC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Century Therapeutics Inc (IPSC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Century Therapeutics Inc (IPSC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Century Therapeutics amends chief scientific officer contract to part-time role By Investing.com - Investing.com South Africa
Century Therapeutics amends chief scientific officer contract to part-time role - Investing.com India
Century retains Chad Cowan as part-time Chief Scientific Officer with reduced pay - TradingView
Century Therapeutics (IPSC) shifts Chief Scientific Officer to part-time role with new pay terms - Stock Titan
Century Therapeutics SVP Carr sells $3,691 in company stock By Investing.com - Investing.com India
Century Therapeutics SVP Carr sells $3,691 in company stock - Investing.com
Century Therapeutics executive Gregory Russotti sells $5,767 in stock By Investing.com - Investing.com Nigeria
Century Therapeutics executive Gregory Russotti sells $5,767 in stock - Investing.com
Century Therapeutics (IPSC) executive sells shares to cover RSU tax withholding - Stock Titan
Tax-related share sale by Century Therapeutics (IPSC) SVP Carr - Stock Titan
Century Therapeutics (IPSC) CEO reports 13,849-share tax withholding on RSU vesting - Stock Titan
Century Therapeutics (IPSC) CSO reports tax withholding of shares and restated holdings - Stock Titan
Century Therapeutics Shareholders Approve Directors and Share Increase - The Globe and Mail
Here's Why We're Watching Century Therapeutics' (NASDAQ:IPSC) Cash Burn Situation - Yahoo Finance
Century Therapeutics (IPSC) director Alessandro Riva granted 74,000 stock options - Stock Titan
Director Daphne Quimi receives 74,000 stock options at Century Therapeutics (NASDAQ: IPSC) - Stock Titan
Century Therapeutics (IPSC) director receives grant of 74,000 stock options - Stock Titan
Century Therapeutics (IPSC) director granted 74,000 stock options at $2.24 - Stock Titan
Century Therapeutics (IPSC) awards 74,000 stock options to director Kimberly Blackwell - Stock Titan
Century Therapeutics (IPSC) shareholders back higher authorized shares and board slate - Stock Titan
Insider sale notice for IPSC (NASDAQ: IPSC) — 2,584 shares planned; prior disposals listed - Stock Titan
Century Therapeutics (IPSC) Reports Positive Preclinical Results For Diabetes Cell Therapy CNTY-813 - Insider Monkey
10 Hot Biotech Stocks Under $5 to Buy - Insider Monkey
Piper Sandler Reaffirms Their Buy Rating on Century Therapeutics (IPSC) - The Globe and Mail
Mizuho Securities Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Century Therapeutics (IPSC) executive logs small automatic share sale for taxes - Stock Titan
Century Therapeutics (IPSC) SVP’s automatic 249-share sale covers RSU tax withholding - Stock Titan
Century Therapeutics (NASDAQ: IPSC) CEO has 463 shares withheld for RSU taxes - Stock Titan
Century Therapeutics, Inc. (IPSC) Presents at American Diabetes Association (ADA) 86th Scientific SessionsSlideshow (NASDAQ:IPSC) 2026-06-09 - Seeking Alpha
Century Therapeutics, Inc. (IPSC) Stock Price, News, Quote & History - Yahoo! Finance Canada
Century Therapeutics Advances CNTY-813 Diabetes Cell Therapy - TipRanks
Century Therapeutics presents preclinical data on diabetes therapy By Investing.com - Investing.com South Africa
Century Therapeutics presents preclinical data on diabetes therapy - Investing.com
Century Therapeutics (NASDAQ: IPSC) details CNTY-813 diabetes cell therapy data - Stock Titan
Experimental islet therapy targets Type 1 diabetes without immunosuppression - Stock Titan
1.95%
2.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):